News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Dorsavi.
RELATED STOCKHEAD STORIES
News
Closing Bell: Local markets have made just a terrific recovery as iron ore bounces back
News
ASX Small Cap Lunch Wrap: Fear as ASX falls and a surprise AI buy emerges
News
Top 10 at 10: AI, big gold hits, and a $65m cash windfall
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX ends higher but iron’s ordinary problem isn’t going away
News
In Case You Missed It: New niobium and REE projects plus scaffold distribution deals
Health & Biotech
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
News
Top 10 at 10: All eyes are on Azure, SQM, and Gina
News
CLOSING BELL: And the Oscar for Best Performing Company in a Comedy Drama goes to…
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Memphasys plans in vivo studies in Japan, Canada; ECS sells Tassie assets
Health & Biotech
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
Health & Biotech
ASX Health Stocks: dorsaVi gets ISO certification; Actinogen to begin Phase 2 trial
Health & Biotech
Check Up: Rhythm plans TGA submission and pig tissue MOU fails to impress
Health & Biotech
ASX Health Stocks: Genetic Technologies jumps after EasyDNA acquisition ups cash receipts by $850k
News
Closing Bell: ASX rises again, hits all time high
Health & Biotech